Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized Phase II Trial in NSCLC Stage IV et IIIB in Elderly Dependent Patients With Evaluation of the Sequence Gemcitabine First Line Followed by Erlotinib When Progression Versus Erlotinib First Line Followed by Gemcitabine When Progression.

NCT00419042 is registered in ClinicalTrials.gov with Groupe Francais De Pneumo-Cancerologie as lead sponsor.

NCT NCT00419042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00419042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized Phase II Trial in NSCLC Stage IV et IIIB in Elderly Dependent Patients With Evaluation of the Sequence Gemcitabine First Line Followed by Erlotinib When Progression Versus Erlotinib First Line Followed by Gemcitabine When Progression.
Lead sponsor
Groupe Francais De Pneumo-Cancerologie
Phase
Observational
Overall status
Completed
Start date
July 31, 2006
Completion date
March 31, 2010
Enrollment
100 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer